• Early stage detection for colon cancer in immunological approach
• Research Partner: PAI CHAI University, Chungnam National University Hospital
• New solid cancer treatment(ATIMPISTATIN)
Government task (to find the optimal indications for commercialization of ATIMPISTATIN for new solid
cancer treatment and non-clinical trial)
Foot-and-mouth disease (FMD) is one of the highly contagious acute viral epidemics of cattle and swine. It is an animal infectious disease that that affects all cloven hoofed animals, such as cattle, sheep, pigs etc and is highly contagious, which is a big problem now. Foot-and-mouth disease has seven serotypes : O, A, C, SAT-1, SAT-2, SAT-3 and Asia-1. It is characterized by the presence of blisters on the hooves, which can lead to poor walking, weight loss or mortality.
In addition to different serotypes in FMD, variants among serotypes, and variants exist within each serotypes, making vaccine production difficult. In other serotypes, immunity does not work, so it is important to apply them individually according to serotype. To date, FMD vaccines are a method of injecting an inactivated virus into an inoculation target.
On the other hand, FMD Vaccine developed by Pharos Vaccine is characterized by its ability to match and optimize each virus subtype by recombinant vaccine method using microorganisms instead of conventional cell culture methods.
These techniques are produced in a manner similar to the production of biopharmaceuticals using microorganisms and are attractive in that they are less expensive than the conventional cell culture methods and can be made into an optimal combination.
Pharos Vaccine and Biocurepharm has contracted about production and sales in the oversea in 2016.
|Material name||Problems with existing vaccines||Pharos FMD vaccine|
|Virus antigen application||• Longer time and higher cost for mass production of vaccines such as viruses, cell lines and incubation times||• Modification of the vaccine epitope allows for the production of vaccines that can be accurately matched for less cost and the development of optimized strains.|
|Risk of live vaccine||
• Possible virus outbreak during production process
• Possibility of active virus contamination in final production process
|• There is no possibility of virus break or contamination using recombinant protein.|
• Cell and virus culture systems (relatively high cost and long incubation times are required)
• Facility enhancement costs to prevent virus outbreak
• Microbial production systems (relatively simple, low cost)
• Virus spill prevention facility is unnecessary.